Mcl-1 as a “barrier” in cancer treatment: Can we target it now?

Pervushin, N.V.; Senichkin, V.V.; Zhivotovsky, B.; Kopeina, G.S.

Статья опубликована в высокорейтинговом журнале

Информация о цитировании статьи получена из Scopus
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 16 декабря 2020 г.

Авторы: Pervushin Nikolay V., Senichkin Viacheslav V., Zhivotovsky B., Kopeina Gelina S.
Журнал: International review of cell and molecular biology
Номер: 351
Год издания: 2020
Издательство: Elsevier BV
Местоположение издательства: Netherlands
Первая страница: 23
Последняя страница: 55
DOI: 10.1016/bs.ircmb.2020.01.002
Аннотация: During the last two decades, the study of Mcl-1, an anti-apoptotic member of the Bcl-2 family, attracted researchers due to its important role in cancer cell survival and tumor development. The significance of Mcl-1 protein in resistance to chemotherapeutics makes it an attractive target in cancer therapy. Here, we discuss the diverse possibilities for indirect Mcl-1 inhibition through its downregulation, for example, via targeting for proteasomal degradation or blockage of translation and transcription. We also provide an overview of the direct blocking of protein-protein interactions with pro-apoptotic Bcl-2 family proteins, including examples of the most promising regulators of Mcl-1 and selective BH3-mimetics, which at present are under clinical evaluation. Moreover, several approaches for the co-targeting of Mcl-1 and other proteins (e.g., CDKs) are also presented. In addition, we highlight the broad spectrum of problems that accompanied the discovery and development of effective Mcl-1 inhibitors.
Добавил в систему: Первушин Николай Викторович

	ИСТИНА	Войти в систему Регистрация
	ИПМех РАН
	Главная Поиск Статистика О проекте Помощь

ИСТИНА

ИПМех РАН

Mcl-1 as a “barrier” in cancer treatment: Can we target it now?статья

Прикрепленные файлы